Enhancing Translational Research Across the Drug Development Cycle
Discovering and developing oncology therapeutics requires consideration of very specific clinical and molecular characteristics within targeted patient populations, and even sub-populations. You can support your oncology drug development programs and translational research with Champions Oncology PDX models, the most highly-characterized, clinically-relevant cohorts of PDX models to optimally predict success and accelerate the drug development process.
Relevant Research from Discovery to Drugs that Make a Difference
Whether you are developing chemotherapies, targeted inhibitors or immuno-oncology agents, Champions TumorGraft PDX models cost-effectively guide decision making across the entire drug development life cycle.
The Champions TumorGraft® patient-derived xenograft (PDX) platform was developed so that you can leverage the most highly-characterized, clinically-relevant cohorts of PDX models to optimally predict success in compound development, accelerating the drug development process.
Champions Oncology is a leader in solid tumor PDX models, a pioneer in leukemia models and studies, and has specialized mouse models that support the engraftment of human cells and tissues, to accelerate efficacy and safety testing of novel immunotherapies.
Contact us to enhance translatability, accelerate oncology drug development and derisk clinical trials.
To learn about Champions Oncology Preclinical Solutions, click here.
To learn about Champions Oncology Clinical Solutions, click here.
To learn more about establishing a Strategic Partnership with Champions Oncology, click here.